The following is a summary of the Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript:
Financial Performance:
Capricor reported Q3 2024 revenues of approximately $2.3 million, a decrease from $6.2 million in Q3 2023.
The net loss for Q3 2024 increased to approximately $12.6 million from $6.4 million in Q3 2023.
Business Progress:
Capricor is on track to complete the submission of its BLA for deramiocel, a therapy for DMD cardiomyopathy, by the end of 2024, with FDA feedback expected by Q1 2025.The company has expanded manufacturing capabilities, establishing a commercial manufacturing facility in San Diego to meet anticipated market demand.
Opportunities:
Capricor is preparing for potential commercial launch of deramiocel, targeting approximately 8,000 DMD patients in the U.S., and anticipates rapid adoption upon approval.
New market opportunities in Europe and Japan through partnerships with Nippon Shinyaku, including milestone payments totaling $1.5 billion, and revenue sharing.
Risks:
The uncertainty of receiving FDA approval for deramiocel, with a planned advisory committee potentially affecting the approval process.
Manufacturing scale-up must align with market demands and regulatory expectations, posing risks to meeting projected timelines and market launch.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
